Efficacy of a bivalent killed whole-cell cholera vaccine over five years: a re-analysis of a cluster-randomized trial. by Fong, Youyi et al.
Fong et al. BMC Infectious Diseases  (2018) 18:84 
https://doi.org/10.1186/s12879-018-2981-4
RESEARCH ARTICLE Open Access
Efficacy of a bivalent killed whole-cell
cholera vaccine over five years: a re-analysis of
a cluster-randomized trial
Youyi Fong1,2, M. Elizabeth Halloran1,2, Jin Kyung Park3, Florian Marks3,6, John D. Clemens4 and
Dennis L. Chao1,5*
Abstract
Background: Oral cholera vaccine (OCV) is a feasible tool to prevent or mitigate cholera outbreaks. A better
understanding of the vaccine’s efficacy among different age groups and how rapidly its protection wanes could help
guide vaccination policy.
Methods: To estimate the level and duration of OCV efficacy, we re-analyzed data from a previously published
cluster-randomized, double-blind, placebo controlled trial with five years of follow-up. We used a Cox proportional
hazards model and modeled the potentially time-dependent effect of age categories on both vaccine efficacy and risk
of infection in the placebo group. In addition, we investigated the impact of an outbreak period on model estimation.
Results: Vaccine efficacy was 38% (95% CI: -2%,62%) for those vaccinated from ages 1 to under 5 years old, 85% (95%
CI: 67%,93%) for those 5 to under 15 years, and 69% (95% CI: 49%,81%) for those vaccinated at ages 15 years and older.
Among adult vaccinees, efficacy did not appear to wane during the trial, but there was insufficient data to assess the
waning of efficacy among child vaccinees.
Conclusions: Through this re-analysis we were able to detect a statistically significant difference in OCV efficacy
when the vaccine was administered to children under 5 years old vs. children 5 years and older. The estimated
efficacies are more similar to the previously published analysis based on the first two years of follow-up than the
analysis based on all five years.
Trial registration: ClinicalTrials.gov identifier NCT00289224
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Background
An estimated 3 million cholera cases occur each year,
about 100,000 of which are fatal [1, 2]. Although the
disease is preventable with the provision of clean water
and sanitation facilities, this would not be feasible in the
near-term in most cholera-endemic regions. A short-term
solution may be the use of oral cholera vaccine (OCV).
Vietnam regularly uses OCV to control cholera, and other
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countries with endemic cholera are currently considering
this option [3–5]. Improved estimates of the effective-
ness of mass vaccination and the duration of protection,
thought to be 3 to 5 years [6, 7], would be useful when
planning mass OCV deployment in settings with limited
resources.
In 2006, over 66,000 people received two doses of either
OCV or a placebo in a large cluster-randomized, double-
blind, placebo-controlled trial in Kolkata, India [8]. The
vaccine was found to be safe and effective at the two-
year interim analysis [8], and the vaccine was licensed
in India in 2009 and prequalified by the World Health
Organization (WHO) in 2011. The final analysis, after
5 years of follow-up, found that the vaccine conferred
protection over 5 years, at least among older children
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and adults [7], but important questions remained unan-
swered. Rather than waning, protective efficacy appeared
to fluctuate with no obvious trend during the 5 years of
follow-up, and the study, which was not powered to esti-
mate efficacy by age, did not find statistically significant
efficacy differences among age groups.
Here, we re-analyze results from the Kolkata cholera
vaccine trial in order to study the efficacy of OCV in
different age groups and to look for evidence of waning
efficacy over time. Strictly speaking, because of the clus-
ter randomized design of the trial, we are estimating the
total effectiveness of vaccination, which include the direct
and indirect effects [9]. Here, we use the term vaccine
efficacy for consistency with previous published results
from this trial. Analyzing outcomes from a trial with long
follow-up presents challenges. Young children in cholera-
endemic settings have the highest risk of illness, but their
risk should decline as they age, possibly affecting esti-
mates of both cholera risk by age and vaccine efficacy. In
addition, a large outbreak occurred in March-April 2010
during the fourth year of the trial [10], which accounted
for about one quarter of the total cholera cases during the
trial. The outbreak did not affect all geographic regions
and age groups equally, which could affect analyses using
age and place of residence as covariates. We address these
concerns by comparing models that use different assump-
tions about a vaccinated or unvaccinated individual’s risk
of cholera as he or she ages, and by comparing results
when including or excluding events that occurred during
the large cholera outbreak.
Methods
Data
The design and implementation of the OCV trial
(ClinicalTrials.gov identifier: NCT00289224) has been
described in detail [8]. Briefly, the trial was conducted in
three wards of the urban slums of Kolkata, India, with a
population of about 109,000. Study clusters were defined
by dwellings, each of which comprises one or more house-
holds with shared access to water and bathrooms or
latrines. Clusters were randomized 1:1 to cholera vaccine
or heat-killed Escherichia coli K12 placebo stratified by
ward of residence (29, 30 and 33) and cluster size (20
or fewer individuals or more than 20 individuals dur-
ing a pre-study census). Those one year old and older
and not pregnant were eligible to participate in the trial.
The first vaccine dose was administered between July 27
and August 13, 2006. The second dose was administered
between August 27 and September 20, 2006. Only those
who received both doses of OCV or placebo were con-
sidered in the per-protocol analyses. The per-protocol set
contains 31,619 OCV and 34,596 placebo recipients. Rec-
tal swabs were obtained from individuals presenting at
local clinics with loose stools and were cultured to detect
Vibrio cholerae. There were 69 and 219 individuals who
had culture-confirmed cholera among participants in the
vaccine and treatment arms, respectively, during the five
years of follow-up [7]. Three participants had culture-
confirmed cholera twice, but only the first episodes were
included in the analyses.
Statistical analysis
In keeping with previous analyses [7, 8], we analyzed
only the first episodes of cholera of each participant
and excluded events that occurred less than 14 days
after each individual’s second (and final) dose of OCV
or placebo. Participants with events within 14 days of
their second doses were removed from the analysis. Par-
ticipants were right-censored when they had cholera,
changed households, died, or when the study concluded
in 2011. Also in keeping with previous analyses, time
to event was treated as the time in days since the par-
ticipant’s second dose of vaccine or placebo. To study
the impact of the large outbreak that occurred in the
fourth year of the study (March–April 2010) on the anal-
ysis, we also performed analyses in which the partici-
pants who are either censored or infected during the
outbreak period were excluded from analysis (Fig. 1).
The outbreak-free dataset contains 31,393 vaccinees and
34,331 placebo recipients. The distribution of cases by
ward and cluster size in the full and outbreak-free data
sets are in Additional file 1: Table S1. The distribu-
tion of cases by age at baseline and age at risk in the
full and outbreak-free data sets are in Additional file 1:
Table S2. The distribution of cases by vaccine arm and age
group at risk in the full and outbreak-free data sets are
in Additional file 1: Table S3. Additional file 2: Figure S1
shows the survival curves stratified by vaccination status
and age group at baseline for the full dataset.
To compare different mechanisms that could describe
age-dependent OCV efficacy, we tested four Cox mod-
els with different age group and treatment interaction.
The four models have the same degrees of freedom and
contained the same randomization stratification variables
(ward of residence and cluster size) as well as addi-
tional characteristics of households that were used in
the previously published per-protocol analysis [7]: home
ownership status, household has a member with a stable
occupation, household income is above the median, and
household’s distance to the nearest water body is above
the median. The four models differ only in how the age
groups are defined for the vaccine effect and the nat-
ural risk (risk of cholera infection in the placebo arm).
The first model (baseline/baseline, or B/B) assumed that
both the vaccine efficacy and natural risk were associated
with the age group of individuals at baseline (i.e., at the
beginning of the trial), the second model (baseline/time-
dependent, or B/T) assumed that the vaccine effect was
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Fig. 1Monthly number of culture-confirmed cholera cases during the study. The number of confirmed cases among all per-protocol study
participants are indicated by the bars, with portions shaded gray to indicate the subset randomized to OCV. A large outbreak occurred in March–April
2010, and the bars representing these two months are indicated with black dots
associated with an individual’s age at baseline and the
natural risk was associated with the time-dependent age
group, the third model (time-dependent/time-dependent,
or T/T) assumed that both the vaccine efficacy and nat-
ural risk were associated with the time-dependent age
group, the last model (time-dependent/baseline, or T/B)
assumed that the vaccine effect was associated with time-
dependent age group and the natural risk was associated
with an individual’s age at baseline. The model equations
are in Additional file 3: Supplementary Text. We fit these
four models to both the full dataset and an “outbreak-free”
dataset that removed subjects with outcomes or censoring
events during the major outbreak in 2010.
All Cox models were fitted using the survival package
in the R statistical programming system (R Foundation for
Statistical Computing; Vienna, Austria) [11]. Cox mod-
els with time-dependent age groups were fitted following
[12]. To account for cluster randomization, all covariance
estimates were robust sandwich estimates [13]. Tests of
the proportional hazards assumption in the Cox model
were performed using Schoenfeld residuals according to
[14] using the identity transformation. The test of overall
vaccine efficacy (VE) by age group interaction was per-
formed by a Wald chi-squared test with two degrees of
freedom. To plot the time trends of vaccine efficacy, we
followed [15] and used a method based on the smoothed
scaled Schoenfeld residuals [14]. The VE plots were made
using the R function VEplot in the kyotil package, which
can be downloaded from the Comprehensive R Archive
Network (http://cran.r-project.org/).
To compare the different Coxmodel fits, likelihood ratio
tests cannot be used because the models are not nested.
Instead, we used the Bayesian information criterion [16]
to help with model choice. Since BIC approximates the
Bayes factor, we use the proposed rules for evaluating the
strength of evidence in Bayes factors [17] to evaluate the
differences in BIC. As the four models all have the same
degrees of freedom, the difference in BIC is the same as
the difference in twice the log likelihood.
Results
The only model fits that did not violate the propor-
tional hazards assumption globally were the B/T and T/T
models fit to the outbreak-free dataset, while the other
six model fits rejected the proportional hazards assump-
tion in the global test with p ranging from 0.009 to
less than 0.001 (Table 1, Additional file 1: Table S4 and
S5). Among the models fit to the outbreak-free dataset,
the B/T model has the best likelihood: twice the log
likelihood ratio between the B/T and T/T models is 8,
and twice the log likelihood ratio between the T/T and
B/B models is 25. Thus, the evidence for B/T or T/T
against B/B model can be categorized as strong, while
the evidence for B/T against T/T can be considered
as positive. These results suggest that the most reason-
able model fit is the B/T model fit to the outbreak-free
dataset.
In the B/T model fit to the outbreak-free data, the risk
of culture-confirmed cholera infection in the placebo arm
was the lowest among adults (those 15 years old and older)
and highest among young children (those under 5 years
old, see Table 2). Older children (ages 5 to under 15 years)
had the highest VE (85%, 95% CI: 67%,93%), followed
by adults (69%, 95% CI: 49%,81%), then young children
(38%, 95% CI: -2%,62%). The VE for older children was
significantly higher than the VE among young children
(p = 0.002) and also higher, but not significantly, than
the VE among adults (p = 0.106). Considering the natural
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Table 1 Protective efficacy against culture-confirmed cholera of several risk factors
B/Ba B/Tb T/Tc
Fulld Outbreak-freee Full Outbreak-free Full Outbreak-free
1-HRf PH testg 1-HR PH test 1-HR PH test 1-HR PH test 1-HR PH test 1-HR PH test
Vaccine efficacy
ages 1 to <5 years 0.45* 0.970 0.38 0.351 0.34 0.250 0.38 0.417 0.47* 0.931 0.44* 0.780
ages 5 to <15 years 0.67** 0.016 0.84** 0.617 0.71** 0.052 0.85** 0.806 0.59** 0.028 0.72** 0.217
ages 15 years and older 0.74** 0.008 0.69** 0.023 0.73** 0.025 0.69** 0.050 0.73** 0.058 0.71** 0.046
Participant age
1 to <5 years (ref) 0.0 0.0 0.0 0.0 0.0 0.0
5 to <15 years 0.69** 0.088 0.65** 0.011 0.74** 0.069 0.78** 0.249 0.77** 0.317 0.80** 0.542
15 years and older 0.81** 0.000 0.80** 0.000 0.88** 0.011 0.89** 0.043 0.89** 0.061 0.89** 0.095
Ward of residence
ward 29 (ref) 0.0 0.0 0.0 0.0 0.0 0.0
ward 30 0.40** 0.000 0.16 0.102 0.39** 0.000 0.15 0.209 0.39** 0.000 0.15 0.243
ward 33 0.07 0.979 -0.02 0.610 0.07 0.941 -0.01 0.719 0.07 0.755 -0.01 0.751
Large cluster -0.61 0.382 -0.43 0.026 -0.60 0.403 -0.43 0.023 -0.60 0.384 -0.42 0.025
Own house 0.24 0.189 0.34* 0.549 0.24 0.351 0.34* 0.668 0.24 0.367 0.35* 0.715
Stable occupation 0.27 0.644 0.27 0.539 0.27 0.628 0.27 0.583 0.27 0.527 0.27 0.560
High income 0.32** 0.662 0.38** 0.125 0.32** 0.784 0.38** 0.109 0.32** 0.954 0.38** 0.121
Far from water -0.31 0.013 -0.09 0.476 -0.31 0.025 -0.08 0.627 -0.31 0.044 -0.09 0.683
Global testh 0.000 0.003 0.004 0.312 0.004 0.233
Log lik ratioi 106 122 118
a both vaccine and age effect are estimated for age group at baseline
b vaccine effect is estimated for age group at baseline, age effect is estimated using time-dependent age groups
c both vaccine effect and age effect are estimated using time-dependent age groups
d all participants were included
e participants with events during March–April 2010 were excluded
f 1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect. Significant terms (p < 0.05) are marked with * and highly significant terms (p <
0.01) are marked with **
g p from test of proportional hazards (PH) assumption
h global test of proportional hazards assumption
i log likelihood ratio relative to a Cox model with no covariate
Table 2 Point estimates and 95% confidence intervals for OCV efficacy by time of vaccination and risk of culture-confirmed cholera by
age at time of risk. Estimates are from the B/T model
Fulla Outbreak-freeb
1-HR (95% CI)c 1-HR (95% CI)
Vaccine efficacy
ages 1 to <5 years 0.34 (-0.09, 0.60) 0.38 (-0.02, 0.62 )
ages 5 to <15 years 0.71 (0.48, 0.84) 0.85 (0.67, 0.93)
ages 15 years and older 0.73 (0.58, 0.83) 0.69 (0.49, 0.81)
Participant age
ages 1 to <5 years (ref) 0 0
ages 5 to <15 years 0.74 (0.62, 0.83) 0.78 (0.66, 0.86)
ages 15 years and older years 0.88 (0.82, 0.92) 0.89 (0.83, 0.93)
a all participants were included
b participants with events during March–April 2010 were excluded
c 1-hazard ratio, which can be interpreted as the protective efficacy for the vaccine effect
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age-related risk and VE together, the hazard ratio of a vac-
cinated older child relative to an unvaccinated young child
and that of a vaccinated adult with respect to the same
reference group are 0.033 and 0.034, respectively.
To check whether the VE differs by age group, we
test the null hypothesis that there is no overall differ-
ence between the estimated VE between age groups by a
generalized Wald test. The results show that the overall
vaccine efficacy by age group interactionwas highly signif-
icant (p = 0.007) in the B/T model fit to the outbreak-free
data (Additional file 1: Table S6). In contrast, the VE is not
significantly different between age groups (p = 0.082) in
the B/B model fit to the full dataset, which is consistent
with the results from the previous 5-year analysis [7].
Comparing the B/T model fits using the full and
outbreak-free datasets, the estimated associated risk of
living in ward 30 relative to ward 29 was highly signifi-
cant (p < 0.001) in the fit using the full dataset but not in
the fit using the outbreak-free dataset. This was consis-
tent with the fact that ward 29 was most affected by the
outbreak and ward 30 was not affected at all (Additional
file 1: Table S1). In addition, VE among older children was
higher when themodel was fit to the outbreak-free dataset
than when the full dataset was used.
The estimated VE over time for each age group based
on fitting the B/T model to the outbreak-free dataset
is shown in Fig. 2. Among adults, there was a trend of
increasing VE near the end of the trial (p = 0.050 with-
out multi-testing adjustment). Among both young and
older children, the VE fluctuated, but the statistical evi-
dence was too weak to conclude anything about trends
over time. In addition, the confidence intervals of the esti-
mated VE excluded 0 in year 5 in both older children and
adults but not in young children.
Discussion
This re-analysis of a large Kolkata cholera vaccine trial
showed that inclusion or exclusion of the large outbreak
in the fourth year of the trial and treating age group
as a fixed or time-dependent covariate could have large
impacts on the estimated covariate effects on culture-
confirmed cholera. The preferred model fit is a hybrid
model fit to the outbreak-free data that lets the age group
effect be associated with time-dependent age group and
the vaccine effect be associated with age group at base-
line. Our re-analyses provide additional evidence that
the efficacy of OCV varies between different age groups,
and suggest that the efficacy among the older children
and adults lasted five years in this cholera-endemic set-
ting. We also looked for evidence of waning of effi-
cacy, and we found no evidence, at least among adult
vaccinees.
The trial had not originally been powered to estimate
differences in VE across age groups, but our re-analysis
found more definitive evidence supporting age group-
dependent VE than the previous analysis. We found VE
to be higher among older children than among young
children (p = 0.002) or adults (p = 0.106). The over-
all significance is 0.007. The same trend had also been
observed in an earlier analysis using only 2 years of follow-
up but that result was not statistically significant (overall
p = 0.07), probably due to the smaller number of events
observed [8]. In the previously published analysis using
all 5 years of follow-up, adults had the highest estimated
VE [7]. The lower VE among older children observed in
that study, compared to both the 2-year analysis and ours,
can be explained by the inclusion of the March–April
2010 outbreak, which appeared to have disproportionately
affected older children (Additional file 1: Table S3). Over-
all, our age-specific OCV efficacy point estimates of 38%,
85%, and 69% for children under 5 years old, children older
than 5 and younger than 15, and individuals 15 years old
or older, respectively, look more similar to the published
estimates that used the first two years of follow-up (49%,
87%, and 63% [8]) than those using all five years (42%, 68%,
and 74% [7]).
The age of participants changed substantially during the
5 years of follow-up. When age enters into a model non-
linearly, e.g., as an age group variable, whether the age
is treated as a fixed or time-dependent variable impacts
Fig. 2 Estimated protective efficacy of OCV over time. Panels plot vaccine efficacy for age groups 1 to under 5 years old (left), 5 to under 15 years old
(middle), and 15 years old and older (right). Efficacy estimates are based on model B/T fit to the outbreak-free dataset. 95% point-wise confidence
intervals are shown as dashed lines
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the outcome of the analysis [18]. In most published anal-
yses of clinical trials, age has been treated as fixed. One
reason for this may be that the duration of most tri-
als is not long enough to make a material difference to
whether or not the age variable is treated as a time-
dependent variable. The Kolkata trial analyzed here has
5 years of follow-up and our analyses have demonstrated
the importance of treating age group as a time-dependent
variable.
An innovative aspect of our analyses is that we decou-
ple the age group that impacts the vaccine effect covariate
and the age group that impacts the natural risk. There
are four possible combinations: B/B, B/T, T/T and T/B,
where the first letter denotes whether VE depends on
baseline or time-dependent age group and the second
letter denotes whether natural risk depends on baseline
or time-dependent age group. A priori, it seems biologi-
cally more plausible that the natural risk should depend
on the time-dependent age group and not on the age at
vaccination. This is because as people age, their behav-
ior and life history change and those are likely to impact
cholera risk. It also seems more likely that vaccine efficacy
depends more on the age group at vaccination than on
the time-dependent age group, since the vaccine-elicited
immune responses differ by the age at the time of vac-
cination [19]. Based on these reasonings, the B/T is the
most biologically reasonable model while the T/B model
is the least. Results from the four fitted models (Table 1
and Additional file 1: Table S4) support the idea that the
B/T model is the best model, and the fitted B/T model
gives us additional insights over the more conventional
B/B model. The estimated hazard ratio between the mid-
dle and youngest age groupwas 0.22 by the B/Tmodel, but
the B/B model gave a more attenuated estimate 0.35. This
attenuation can be explained by the fact that the younger
children group as defined by the B/B model is actually a
mixture of the younger and older children at the time of
infection.
The occurrence of a major outbreak during follow-up
presents an analytical challenge. Our choice of remov-
ing the outcomes and censoring events occurring during
the outbreak is a simple approach, and it allows us to
cleanly assess vaccine efficacy and the effects of other
covariates under non-outbreak situations. For example,
removing the outbreak from the analysis set results in
an upwards shift of the estimated VE among the older
children (ages 5 to 15 years) from 0.71 to 0.85. Further-
more, in combination with the use of the B/T model
for encoding age group, the evidence for the age group-
vaccine treatment interaction grows from borderline (p-
value 0.082) to highly significant (p-value 0.007). It should
be noted that vaccinated individuals were protected dur-
ing the outbreak and exclusion from the analysis does not
imply a lack of efficacy during acute outbreaks. Exclusion
of the censored and infected subjects during the out-
break has some drawbacks. For example, it is difficult to
determine how it may have affected the randomization.
We had considered other approaches. One temptation
is to use an indicator variable to denote the outbreak
period and include the variable in a model to analyze
the full dataset. The advantage of this approach is that
all data is put to use, but the model is difficult to inter-
pret because the outbreak is not an attribute of the
subjects, but rather an outside force that happens at a
particular time and place. One may also envision a com-
peting risk model where the events during the outbreak
are treated as coming from an alternative cause. As the
outbreak only occurs in a relatively short period, there
is probably little benefit to take this more complicated
approach.
An interesting observation from our analysis is that the
cholera risks of a vaccinated older child (ages 5 to 15
years) and a vaccinated adult (15 years old and older) are
very close, despite the fact that unvaccinated adults have
a lower risk of cholera than an unvaccinated older child.
Using young children (ages 1 to 5 years) from the placebo
group as reference, the risks experienced by both afore-
mentioned groups are 30-fold lower. This suggests that
the vaccine reduced the risk level of those 5 years old and
older to a similarly low level.
The results presented here may be relevant for future
routine OCV deployment plans in endemic regions where
cholera strikes frequently. Our analyses show that OCV
could provide 5 years of high-quality protection for those
over 5 years old with no evidence of waning among adults,
suggesting that they might not need to be re-vaccinated
frequently to maintain protection, making mass vacci-
nation more cost-effective in cholera-endemic regions.
However, younger children are at high risk of cholera
in this population and OCV may confer lower protec-
tion, thus re-vaccination when they are older may be
desirable.
The duration of protective efficacy of OCV may differ
in endemic and epidemic regions. Repeated exposure to
V. cholerae may serve as natural boosters for vaccinees,
prolonging their protection [7, 20]. Therefore, vaccine
protection may appear to wane more quickly in popula-
tions exposed to cholera less frequently. OCV use outside
Asia has largely been to prevent or mitigate outbreaks in
populations that do not see cholera every year [21]. OCV
was recently used in reactive campaigns during outbreaks
in Guinea and Haiti, and the VE estimated during these
outbreaks was consistent with the estimates from Kolkata
reported here [22, 23], but the duration of protection in
these populations is not yet known. Additional studies are
needed to estimate how long two doses of OCV can con-
fer protection in populations outside well-studied South
Asian endemic regions.
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Conclusions
In this re-analysis of a large placebo controlled trial, we
found that oral cholera vaccine efficacy was statistically
significantly higher when administered to children 5 years
old and older compared to children under 5 years old,
a difference that had been suspected but not conclu-
sively demonstrated in previous trials. We also found no
evidence of waning vaccine efficacy among adult vacci-
nees over five years of follow-up, so adults might not
require frequent re-vaccination in stable cholera-endemic
populations. These findings should be considered when
vaccinating endemic populations against cholera.
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